High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial

Published:2016-08 Issue:8 Volume:3 Page:e388-e397
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Illerhaus Gerald,Kasenda Benjamin,Ihorst Gabriele,Egerer Gerlinde,Lamprecht Monika,Keller Ulrich,Wolf Hans-Heinrich,Hirt Carsten,Stilgenbauer Stephan,Binder Mascha,Hau Peter,Edinger Matthias,Frickhofen Norbert,Bentz Martin,Möhle Robert,Röth Alexander,Pfreundschuh Michael,von Baumgarten Louisa,Deckert Martina,Hader Claudia,Fricker Heidi,Valk Elke,Schorb Elisabeth,Fritsch Kristina,Finke Jürgen

Publisher

Elsevier BV

Subject

Hematology

Reference38 articles.

1. Trends in survival from primary central nervous system lymphoma, 1975–1999: a population-based analysis;Panageas;Cancer,2005

2. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis;Olson;Cancer,2002

3. Rising incidence of primary central nervous system lymphoma in Kumamoto, Japan;Makino;Surg Neurol,2006

4. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial;Ferreri;Lancet,2009

5. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma;Illerhaus;J Clin Oncol,2006

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study;Signal Transduction and Targeted Therapy;2024-09-04

2. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Annals of Oncology;2024-06

3. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up;HemaSphere;2024-06

4. The notable outcomes of modified thiotepa-based conditioning followed by autologous stem cell transplantation in primary central nervous system lymphomas: A real-life pilot study;2024-05-31

5. Survival outcomes and treatment experience of 124 patients with primary central nervous system lymphoma;Strahlentherapie und Onkologie;2024-03-11